

Anti-VEGFR2/KDR/CD309 Antibody (Olinvacimab)

Introduction

Olinvacimab (TTAC-0001) is a human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binding to KDR with a K_d value of 0.23 nM. Olinvacimab has anti-angiogenic activity. Olinvacimab can be used in the study of recurrent glioblastoma and breast cancer.

Product parameters

Alternative Names	TTAC-0001, TTAC0001, Tanibirumab
Target Accession	P35968
Target	VEGFR2 / KDR / CD309
CAS number	2095504-49-5
Molecular Weight	148.16 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

